Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of “Hold” by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) has earned a consensus recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $7.50.

A number of research analysts have recently weighed in on the stock. Weiss Ratings raised shares of Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 4th. Craig Hallum downgraded Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, June 3rd. Wall Street Zen raised Cardiff Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. TD Cowen downgraded Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, HC Wainwright upgraded Cardiff Oncology from a “neutral” rating to a “buy” rating in a research note on Tuesday.

Get Cardiff Oncology alerts:

View Our Latest Analysis on Cardiff Oncology

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $1,265,000. Flputnam Investment Management Co. purchased a new position in Cardiff Oncology in the 2nd quarter valued at approximately $322,000. X Square Capital LLC purchased a new position in Cardiff Oncology in the 2nd quarter valued at approximately $267,000. GSA Capital Partners LLP bought a new stake in Cardiff Oncology during the 2nd quarter valued at $225,000. Finally, Bank of New York Mellon Corp bought a new stake in Cardiff Oncology during the 2nd quarter valued at $210,000. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology News Roundup

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and issued more favorable earnings forecasts. The firm estimates a 2026 loss of $0.56 per share, better than the broader consensus loss of $0.61, and projects the loss narrowing to $0.33 per share in 2027. Quarterly loss estimates also improve from $0.13 per share in Q3 2026 to approximately $0.08–$0.09 per share during 2027, suggesting expectations for reduced cash burn over time. MarketBeat Cardiff Oncology analyst estimates
• Neutral Sentiment: Analyst sentiment is mixed. A separate report highlights conflicting views among analysts covering Cardiff Oncology, which may limit the impact of HC Wainwright’s Buy rating and keep trading volatile. Analysts conflicted on Cardiff Oncology
• Negative Sentiment: Cardiff Oncology continues to forecast sizable losses. The company is expected to lose $0.56 per share in 2026 and $0.33 per share in 2027, while its latest quarterly results missed the consensus EPS estimate. These losses create ongoing cash-burn and potential financing risks for investors.

Cardiff Oncology Trading Up 1.2%

NASDAQ CRDF traded up $0.01 during trading hours on Friday, hitting $1.31. The company’s stock had a trading volume of 81,404 shares, compared to its average volume of 1,154,983. Cardiff Oncology has a 52 week low of $0.76 and a 52 week high of $3.31. The company has a market capitalization of $102.30 million, a PE ratio of -2.19 and a beta of 1.46. The company’s 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $1.40.

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.06 million. Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. Research analysts anticipate that Cardiff Oncology will post -0.6 EPS for the current fiscal year.

Cardiff Oncology Company Profile

(Get Free Report)

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.

Featured Stories

• Five stocks we like better than Cardiff Oncology
• 3 Zero-Fee ETFs Worth More Than Their Cost
• 3 Nimble Free Cash Flow Names With Light Assets
• Intel’s Ohio Lifeline? Why the SK Hynix Talks Matter
• Generac Plugs into Amazon for an $8B AI-Powered Deal

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.